• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

    1/24/24 8:14:23 AM ET
    $BB
    $CVKD
    $ENSC
    $ETAO
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BB alert in real time by email

    Shares of Netflix, Inc. (NASDAQ:NFLX) shares rose sharply in today’s pre-market trading as the company reported better-than-expected sales for its fourth quarter.

    Netflix reported fourth-quarter revenue of $8.83 billion, which was up 12.5% year-over-year. The total came in ahead of a Street consensus estimate of $8.72 billion. The company reported fourth-quarter earnings per share of $2.11, which missed a Street consensus estimate of $2.21.

    The company, meanwhile, added 13.12 million net paid subscribers in the fourth quarter.

    Netflix shares jumped 10.2% to $542.48 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Getaround, Inc. (NYSE:GETR) gained 50.7% to $0.2771 in pre-market trading after the company announced a new debt facility with Mudrick Capital Management for up to $20 million.
    • Evaxion Biotech A/S (NASDAQ:EVAX) gained 43.2% to $7.15 in pre-market trading after a 13G filing showed Merck & Co reported an 11.4% stake in the company as of December 21, 2023.
    • VS MEDIA Holdings Limited (NASDAQ:VSME) shares jumped 31.7% to $0.4318 in pre-market trading after gaining around 3% on Tuesday.
    • Zoomcar Holdings, Inc. (NASDAQ:ZCAR) shares gained 18.1% to $3.98 in pre-market trading after gaining over 5% on Tuesday. Zoomcar recently appointed Adarsh Menon as President.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) gained 17.8% to $1.05 in pre-market trading. Redhill Biopharma was granted U.S. Patent #11878011 for "Method for Eradicating Helicobacter Pylori Infection in Patients Regardless of Body Mass Index."
    • Nyxoah S.A. (NASDAQ:NYXH) surged 17.7% to $6.59 in pre-market trading after surging over 20% on Tuesday.
    • Greenidge Generation Holdings Inc. (NASDAQ:GREE) shares climbed 15.7% to $4.10 in pre-market trading after falling more than 10% on Tuesday.
    • Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) shares gained 10.7% to $1.14 in pre-market trading.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) shares gained 8.6% to $1.51 in pre-market trading. Ensysce Biosciences shares gained 22% on Tuesday after the company announced FDA Breakthrough Therapy Designation for PF614-MPAR.

    Losers

    • Meta Materials Inc. (NASDAQ:MMAT) shares dipped 16.2% to $0.0560 in pre-market trading. Meta Materials announced a 1-for-100 reverse stock split to regain Nasdaq compliance.
    • BlackBerry Limited (NYSE:BB) shares fell 11% to $3.16 in pre-market trading after the company announced a proposed private offering of $160 million of convertible senior notes.
    • vTv Therapeutics Inc. (NASDAQ:VTVT) shares fell 9.4% to $8.48 in pre-market trading.
    • ETAO International Co., Ltd. (NASDAQ:ETAO) fell 8.9% to $0.2010 after dipping over 20% on Tuesday.
    • Diversified Energy Company PLC (NYSE:DEC) fell 8.9% to $11.74 in pre-market trading.
    • Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) declined 8% to $0.1574 in pre-market trading. Sonoma pharmaceuticals announced the launch of Lumacyn Clarifying Mist direct to consumers for over-the-counter use in the US.
    • Opthea Limited (NASDAQ:OPT) shares fell 7.9% to $2.44 in pre-market trading.
    • HWH International Inc. (NASDAQ:HWH) shares declined 7.3% to $1.78 in pre-market trading after gaining more than 23% on Tuesday.
    • FaZe Holdings Inc. (NASDAQ:FAZE) shares declined 6.9% to $0.2978 in pre-market trading. FaZe Holdings shares jumped 107% on Tuesday after the company announced Rollbit will sponsor its Counter-Strike team.
    • Texas Instruments Incorporated (NASDAQ:TXN) shares dipped 3.7% to $167.88 in pre-market trading after the company reported fourth-quarter financial results.

    Now Read This: Netflix, Tesla And 3 Stocks To Watch Heading Into Wednesday

    Get the next $BB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BB
    $CVKD
    $ENSC
    $ETAO

    CompanyDatePrice TargetRatingAnalyst
    Netflix Inc.
    $NFLX
    3/18/2026$115.00Buy
    Citigroup
    vTv Therapeutics Inc.
    $VTVT
    3/12/2026$44.00Outperform
    Evercore ISI
    Netflix Inc.
    $NFLX
    3/9/2026$105.00Equal Weight
    Wells Fargo
    Netflix Inc.
    $NFLX
    3/2/2026$115.00Equal Weight
    Barclays
    Netflix Inc.
    $NFLX
    3/2/2026$120.00Overweight
    Analyst
    Netflix Inc.
    $NFLX
    2/27/2026$115.00Outperform
    Evercore ISI
    Netflix Inc.
    $NFLX
    2/27/2026Neutral → Buy
    Arete
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    More analyst ratings

    $BB
    $CVKD
    $ENSC
    $ETAO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of SalesFoundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025. Recent Financial and Operating Highlights Fourth quarter gross revenue of €6

    3/19/26 4:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Notice to convene Evaxion's Annual General Meeting

    COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET. The meeting will be held at the company's offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. The agenda and proposals can be found on Evaxion's website, along with other materials: www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/ Contact information Evaxion A/SMads KronborgVice President, Investor Relations & Communication+45 53 54 82 96 [email protected] About Evaxion Evaxion is a pione

    3/19/26 9:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to present new data at AACR Annual Meeting

    Two abstracts accepted for presentationOne abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01Another abstract on the use of Evaxion's AI-Immunology™ platform in developing a personalized cancer vaccine strategy for glioblastoma (brain cancer)Evaxion will also participate in the AACR Oncology Industry Partnering event ahead of the annual meeting COPENHAGEN, Denmark, March 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces two abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting ta

    3/17/26 4:30:00 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BB
    $CVKD
    $ENSC
    $ETAO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Tsimchi Ofer

    3 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    3/19/26 7:35:14 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Evaxion A/S

    3 - Evaxion A/S (0001828253) (Reporting)

    3/18/26 9:13:18 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Evaxion A/S

    3 - Evaxion A/S (0001828253) (Reporting)

    3/18/26 9:12:04 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BB
    $CVKD
    $ENSC
    $ETAO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Netflix with a new price target

    Citigroup resumed coverage of Netflix with a rating of Buy and set a new price target of $115.00

    3/18/26 8:24:18 AM ET
    $NFLX
    Consumer Electronics/Video Chains
    Consumer Discretionary

    Evercore ISI initiated coverage on vTv Therapeutics with a new price target

    Evercore ISI initiated coverage of vTv Therapeutics with a rating of Outperform and set a new price target of $44.00

    3/12/26 8:55:45 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Netflix with a new price target

    Wells Fargo resumed coverage of Netflix with a rating of Equal Weight and set a new price target of $105.00

    3/9/26 9:07:38 AM ET
    $NFLX
    Consumer Electronics/Video Chains
    Consumer Discretionary

    $BB
    $CVKD
    $ENSC
    $ETAO
    SEC Filings

    View All

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    3/19/26 5:04:44 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/19/26 9:10:04 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/19/26 9:00:05 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BB
    $CVKD
    $ENSC
    $ETAO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kovler Jordan sold $4,073 worth of shares (3,133 units at $1.30) and bought $7,800 worth of shares (5,000 units at $1.56), increasing direct ownership by 1% to 152,912 units (SEC Form 4)

    4 - Greenidge Generation Holdings Inc. (0001844971) (Issuer)

    5/23/25 4:02:44 PM ET
    $GREE
    Finance: Consumer Services
    Finance

    Director Krug Christopher J. bought $164,638 worth of shares (125,000 units at $1.32) (SEC Form 4)

    4 - Greenidge Generation Holdings Inc. (0001844971) (Issuer)

    5/20/25 4:01:20 PM ET
    $GREE
    Finance: Consumer Services
    Finance

    Chief Executive Officer Kovler Jordan was granted 12,737 shares and bought $17,600 worth of shares (15,000 units at $1.17), increasing direct ownership by 22% to 151,045 units (SEC Form 4)

    4 - Greenidge Generation Holdings Inc. (0001844971) (Issuer)

    5/20/25 4:01:03 PM ET
    $GREE
    Finance: Consumer Services
    Finance

    $BB
    $CVKD
    $ENSC
    $ETAO
    Leadership Updates

    Live Leadership Updates

    View All

    vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and pro

    3/10/26 4:01:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

    Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion's strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her role as Chief Scientific OfficerSeasoned life science executive Jens Bitsch-Norhave will join as observer and advisor to the Board of Directors with the intention of seeking election at the

    10/27/25 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BB
    $CVKD
    $ENSC
    $ETAO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Getaround Inc.

    SC 13D/A - Getaround, Inc (0001839608) (Subject)

    11/14/24 5:06:28 PM ET
    $GETR
    Rental/Leasing Companies
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

    SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

    11/14/24 4:00:17 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BB
    $CVKD
    $ENSC
    $ETAO
    Financials

    Live finance-specific insights

    View All

    Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of SalesFoundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025. Recent Financial and Operating Highlights Fourth quarter gross revenue of €6

    3/19/26 4:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

    Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and full year of 2025 on Thursday, March 19, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or

    3/5/26 4:05:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care